Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Paul Gillespie

Robert Alan Goodnow, Jr

Sung-Sau So

Nader Fotouhi

Fariborz Firooznia

Sherrie Lynn Pietranico-Cole

Tai-An Lin

Li Chen

Jefferson Wright Tilley

Yun He

Hongying Yun

Robert W Guthrie

Shawn David Erickson

Weiya Yun

Kevin Richard Guertin

Qiang Zhang

Eric Mertz

Kyungjin Kim

Kshitij Chhabilbhai Thakkar

Warren William McComas

Zhenshan Zhang

Achyutharao Sidduri

Qingjie Ding

Lida Qi

Agnieszka Kowalczyk

Chang An Chu

Agostino Perrotta

Nancy-Ellen Haynes

Kang Le

Christophe Michoud

Nathan Robert Scott

Jenny Tan

Pamela Loreen Rossman

Kevin W Anderson

Michael Paul Myers

Matthew Michael Hamilton

Alexander Mayweg

Allen John Lovey

Norman Kong

Romyr Dominique

John Frederick Boylan

Qi Qiao

Nicholas J S Huby

Jianping Cai

John Lawson Roberts

Chun Ma

Prabha Saba Karnachi

John Guilfoyle Mullin, Jr

Jean-Baptiste Blanc

Kenneth Carey Rupert

Joseph Anthony Bilotta

Bruce Lester Banner

Richard Jones

JohnMark Derryberry

Alexander V Mayweg

Robert Alan Goodnow Jr

Nicholas John Silvester Huby

Kevin William DrANDERSON

Kevin William Anderson

The invention is concerned with a compound of formula (I) and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and using the compound of formula (I) as well as pharmaceutical compositions containing such compounds. The compound of formula (I) are SCD1 inhibitors and may be useful in treating cancer. 

Substituted isoxazole amide compounds as inhibitors of stearoyl-CoA desaturase 1 (SCD1)

The invention is concerned with a compound of formula (I) wherein R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament. 

Substituted isoxazole amine compounds as inhibitors of SCD1

There are disclosed are compounds of the formula: wherein R1 and R2 are as disclosed herein,which are eIF4E inhibitors useful in the treatment of cancers. Also disclosed are compositions comprising the compounds, as well as methods of treating cancer using the compounds.

Benzoic acid derivatives

The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein W, X, Y, and R-Rare defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

Naphthylacetic acids

The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Q, W, X, R&#x2014;Rand n are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

Aminotetrahydroindazoloacetic acids

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of inflammatory diseases and disorders such as, for example, asthma and COPD.

Thiazole and thiophene compounds

The present invention relates to compounds according to formula 1, which exhibit cytotoxic activity. The compounds may be used in the treatment of cancer.

Sultam derivatives

The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Q, R1-R3 and n are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein R-Rare defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

Substituted aminotetralines

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

GPR119 receptor agonists

The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein R-R, A, B, Q, W, and X are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

Bi-aryl aminotetralines

The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Q, W, X, R-Rand n are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein X, Q, and R-Rare defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, COPD.

[object Object]

Growing community of inventors

Westfield, NJ, United States of America

Paul Gillespie